Zoetis
Genomics & Genetic Testing · Diagnostic Tests & IVD
Overview
Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on 60 years of experience, we deliver quality medicines and vaccines, complemented by diagnostic products and genetic tests and supported by a range of services.
Funding and backers
Backers
1
Elevate Ventures
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 0.04%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs DENCODA
backs Averna Therapeutics
Similar startupsby what they do, their industry and backers
Averna Therapeutics is creating the last, great missing tool required to break through the most persistent barriers in genetic medicine.
Thyreos develops herpesvirus vaccines and vaccine vectors for the animal health and human health markets. Thyreos vaccines are based on a…
Technology Product Who we are News Contact DENCODA's mission is to address critical research and diagnostic detection challenges. We're…
Animal Vaccine Delivery in Just 30 Minutes. Experience the world's fastest vaccine delivery. Get a complete range of vaccines delivered…
22 January 2017 2017, Feb. 22-23: VEROVACCiNES selected as Emerging Company at ANIMAL HEALTH INVESTMENT Europe, London UK conference 2017.
Genvax Technologies is an animal vaccine company developing next-generation mRNA + nanoparticle vaccines from Ames, Iowa. Our mission is to…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Elevate VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Zoetis: Priced For The Worst, Worth Buying (NYSE:ZTS)
Zoetis Inc. has fallen 71% from its 2021 peak, now trading at 2017 levels, as pricing power eroded and pet medicine volumes declined. Learn more about ZTS stock here.
Read more
Report
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.
Read more
Report
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis maintained its revised guidance for operational revenue declining 3% to 1%, citing weaker U.S. pet-care demand, fewer…
Read more
Report
Zoetis: An Undervalued Compounder Hiding In Plain Sight (NYSE:ZTS)
Zoetis faces near-term pressure from weaker US companion animal demand, increased competition, and margin compression. Learn more about ZTS stock now.
Read more
Report
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity.
Read more
Report
Why Zoetis Shares Plummeted Today
Zoetis reported first-quarter earnings on Thursday, and the market did not like what it saw.
Read more
Report
Show more news